Immucell (ICCC) Long-Term Investments (2014 - 2019)
Immucell's (ICCC) quarterly Long-Term Investments came in at $4117.0 in Q1 2019, down 95.69% YoY from $95557.0 in Q1 2018, and down 89.76% on a QoQ basis from $40209.0 in Q4 2018.
Immucell (ICCC) Long-Term Investments (2014 - 2019) Analysis & Trends
Immucell (ICCC) has 6 years of Long-Term Investments data on file, last reported at $4117.0 in Q1 2019.
- Quarterly Long-Term Investments fell 95.69% year-over-year to $4117.0 in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $4117.0 (down 95.69% YoY) and the FY2018 annual result came in at $40209.0, down 57.92% from the prior year.
- Long-Term Investments declined to $4117.0 in Q1 2019, from $40209.0 in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $489648.0 in Q4 2015 to a low of $4117.0 in Q1 2019.
- A 5-year average of $236376.1 and a median of $96973.5 in 2017 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2015 — Long-Term Investments decreased 1.28% — and 2019, when it sank 95.69%.
- Tracing ICCC's Long-Term Investments over 5 years: stood at $489648.0 in 2015, then retreated by 0.54% to $487000.0 in 2016, then slumped by 80.38% to $95557.0 in 2017, then tumbled by 57.92% to $40209.0 in 2018, then plunged by 89.76% to $4117.0 in 2019.
- The last three Long-Term Investments figures came in at $4117.0 (Q1 2019), $40209.0 (Q4 2018), and $98390.0 (Q3 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 4,117.00 |
| Dec 31, 2018 | 40,209.00 |
| Sep 30, 2018 | 98,390.00 |
| Jun 30, 2018 | 79,283.00 |
| Mar 31, 2018 | 95,557.00 |
| Dec 31, 2017 | 95,557.00 |
| Jun 30, 2016 | 487,000.00 |
| Mar 31, 2016 | 487,000.00 |
| Dec 31, 2015 | 489,648.00 |
| Sep 30, 2015 | 487,000.00 |
| Dec 31, 2014 | 496,000.00 |
| Sep 30, 2014 | 496,000.00 |
| Jun 30, 2014 | 496,000.00 |
| Mar 31, 2014 | 496,000.00 |